Argus Downgrades Mylan (MYL) to Hold

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. LDOS
8. HUM
9. CSCO
10. KTOS

Go back to Argus Downgrades Mylan (MYL) to Hold

Mylan (MYL) & Otsuka Report License Agreement to Commercialize Delamanid (Deltyba) in High-Burden Countries

August 24, 2017 5:51 AM EDT

Otsuka Pharmaceutical Co. Ltd. and Mylan N.V. (NASDAQ: MYL) have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private Limited (Mylan), to commercialize delamanid for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries. Delamanid was discovered and developed, and is currently marketed by Otsuka under the brand name Deltyba.

Under the terms of the agreement, Mylan has been granted an exclusive license by Otsuka to prioritize access to Deltyba in South Africa and India. Both countries are... More